mRNA Technology

Vaccine Development Vaccine Technology Research and Development Lipid Nanoparticles Vaccine Production Therapeutics Drug Development Vaccine Innovation Cancer Research Therapeutic Development Applications Personalized Medicine Pharmaceutical Technology Cancer Therapy Artificial Intelligence Drug Delivery Systems Cancer Vaccines Vaccines Vaccine Delivery Vaccine Delivery Systems mRNA-1083 Lipid Nanoparticle Delivery Clinical Trials Innovations

14 ARTICLES

last mo.

FDA Advisers Unanimously Back Moderna’s mRNA Flu Vaccine

Unanimous advisory support advances the shot toward licensure; final FDA action is due by Aug. 5, with CDC coverage unsettled by ACIP’s inability to convene.

7 ARTICLES

last mo.

NewLimit Raises $435 Million to Advance First Human Trial for Liver Rejuvenation

3 ARTICLES

2mo ago

BioNTech Founders to Exit This Year to Launch New mRNA Company as Stock Slumps on Weak Outlook

15 ARTICLES

4mo ago

Moderna Reaches Up to $2.25 Billion LNP Patent Settlement, Pays $950 Million Upfront

3 ARTICLES

5mo ago

FDA to Review Moderna’s Flu Shot as Shares Rally on Earnings Beat

6 ARTICLES

6mo ago

Moderna, Merck Melanoma Vaccine Shows Durable Five-Year Benefit as Stock Hits 52-Week High

5 ARTICLES

7mo ago

CEPI Puts Up to $54.3 Million Behind Moderna’s H5 mRNA Bird Flu Vaccine for Phase 3

7 ARTICLES

9mo ago

Moderna Scraps CMV Vaccine Program After Phase 3 Failure

9 ARTICLES

11mo ago

HHS Axes $500 Million in BARDA mRNA Vaccine Projects, Drawing Intensifying Warnings

8 ARTICLES

11mo ago

US Cuts $500 Million in mRNA Vaccine Research Funding

7 ARTICLES

this yr.

Membrane-Bound mRNA HIV Vaccine Elicits Neutralizing Antibodies in 80% of Participants

5 ARTICLES

last yr.

Moderna’s mRNA-1010 Flu Vaccine Shows Superior Efficacy in Phase 3 Trial

4 ARTICLES

last yr.

BioNTech to Acquire CureVac for $1.25 Billion to Drive mRNA Cancer Therapy

mRNA Technology

FDA Advisers Unanimously Back Moderna’s mRNA Flu Vaccine

NewLimit Raises $435 Million to Advance First Human Trial for Liver Rejuvenation

Lilly Acquires Engage Biologics for Up to $202 Million

Moderna Jumps on Hantavirus Cruise-Ship Cluster as U.S. Repatriates 17 Citizens

Moderna Beats Q1 Forecast as Overseas COVID Shot Sales Rebound

Moderna Begins Phase III Trial of mRNA Bird Flu Vaccine in UK and US

BioNTech Founders to Exit This Year to Launch New mRNA Company as Stock Slumps on Weak Outlook

Moderna Reaches Up to $2.25 Billion LNP Patent Settlement, Pays $950 Million Upfront

FDA to Review Moderna’s Flu Shot as Shares Rally on Earnings Beat

Moderna, Merck Melanoma Vaccine Shows Durable Five-Year Benefit as Stock Hits 52-Week High

Never miss stories about

mRNA Technology

CEPI Puts Up to $54.3 Million Behind Moderna’s H5 mRNA Bird Flu Vaccine for Phase 3

Moderna Scraps CMV Vaccine Program After Phase 3 Failure

HHS Axes $500 Million in BARDA mRNA Vaccine Projects, Drawing Intensifying Warnings

US Cuts $500 Million in mRNA Vaccine Research Funding

Membrane-Bound mRNA HIV Vaccine Elicits Neutralizing Antibodies in 80% of Participants

Moderna’s mRNA-1010 Flu Vaccine Shows Superior Efficacy in Phase 3 Trial

BioNTech to Acquire CureVac for $1.25 Billion to Drive mRNA Cancer Therapy

Never miss stories about

mRNA Technology